Drug Development Drug Pricing Drug Approval Drug Safety Clinical Trials Weight Loss Drugs Biotechnology Prescription Drugs Drug Regulation Drug Manufacturing
The phase 3 result could establish a new standard of care for patients whose KRAS G12C non‑small cell lung cancer progressed after prior therapy.